Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance.

Trial Profile

Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance.

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs Pioglitazone (Primary)
  • Indications Bipolar I disorders; Bipolar II disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Jan 2013 Planned end date changed from 1 Oct 2011 to 1 Oct 2013 as reported by ClinicalTrials.gov.
    • 04 Aug 2011 Planned end date changed from 1 Feb 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.
    • 02 Jul 2010 Sponsor and lead trial centre (Takeda Pharmaceuticals North America) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top